Expression profiling identifies responder and non‐responder phenotypes to interferon‐β in multiple sclerosis
Open Access
- 1 June 2003
- journal article
- research article
- Published by Oxford University Press (OUP) in Brain
- Vol. 126 (6), 1419-1429
- https://doi.org/10.1093/brain/awg147
Abstract
Autoimmune diseases such as multiple sclerosis are characterized by complex genetic traits and pathomechanisms that translate into clinical heterogeneity. This wide heterogeneity of multiple sclerosis as well as different biological responses to immunomodulatory drugs can be expected to contribute to differential treatment responses. Strategies that dissect the relationship between the treatment response and the biological characteristics in individual patients are valuable not only as a clinical tool, but also in leading to a better understanding of the disease. Here we address the in vitro and ex vivo RNA expression profile under one approved therapy of multiple sclerosis, interferon‐β (IFN‐β, Betaseron), by cDNA microarrays and demonstrate that non‐responder and responder phenotypes to IFN‐β as assessed by longitudinal gadolinium‐enhanced MRI scans and clinical disease activity differ in their ex vivo gene expression profile. These findings will help to better elucidate the mechanism of action of IFN‐β in relation to different disease patterns and eventually lead to optimized therapy.Keywords
This publication has 32 references indexed in Scilit:
- Interferon-β treatment alters peripheral blood monocytes chemokine production in MS patientsJournal of Neuroimmunology, 2002
- Comparison of Gene Expression Patterns Induced by Treatment of Human Umbilical Vein Endothelial Cells with IFN-α2b vs. IFN-β1a: Understanding the Functional Relationship Between Distinct Type I Interferons That Act Through a Common ReceptorJournal of Interferon & Cytokine Research, 2002
- A comparative study of the relative bioavailability of different interferon beta preparationsNeurology, 2000
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000
- Multiple sclerosis: ImmunotherapyCurrent Treatment Options in Neurology, 1999
- Interferon beta-1b treatment modulates TNFα and IFNγ spontaneous gene expression in MSNeurology, 1999
- Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arraysProceedings of the National Academy of Sciences, 1998
- Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseasesProceedings of the National Academy of Sciences, 1998
- Increases in soluble VCAM‐1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon β‐1bAnnals of Neurology, 1997
- Interferon Beta in Multiple SclerosisClinical Immunology and Immunopathology, 1996